JP2011518836A5 - - Google Patents

Download PDF

Info

Publication number
JP2011518836A5
JP2011518836A5 JP2011506453A JP2011506453A JP2011518836A5 JP 2011518836 A5 JP2011518836 A5 JP 2011518836A5 JP 2011506453 A JP2011506453 A JP 2011506453A JP 2011506453 A JP2011506453 A JP 2011506453A JP 2011518836 A5 JP2011518836 A5 JP 2011518836A5
Authority
JP
Japan
Prior art keywords
chloro
docosa
nonaen
tetraazatetracyclo
pentaazatetracyclo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011506453A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011518836A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/041555 external-priority patent/WO2009132202A2/en
Publication of JP2011518836A publication Critical patent/JP2011518836A/ja
Publication of JP2011518836A5 publication Critical patent/JP2011518836A5/ja
Pending legal-status Critical Current

Links

JP2011506453A 2008-04-24 2009-04-23 大環状化合物およびそれらのキナーゼ阻害剤としての使用 Pending JP2011518836A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4754708P 2008-04-24 2008-04-24
US61/047,547 2008-04-24
US12258208P 2008-12-15 2008-12-15
US61/122,582 2008-12-15
PCT/US2009/041555 WO2009132202A2 (en) 2008-04-24 2009-04-23 Macrocyclic compounds and their use as kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2011518836A JP2011518836A (ja) 2011-06-30
JP2011518836A5 true JP2011518836A5 (enExample) 2012-06-14

Family

ID=41100487

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011506453A Pending JP2011518836A (ja) 2008-04-24 2009-04-23 大環状化合物およびそれらのキナーゼ阻害剤としての使用

Country Status (5)

Country Link
US (1) US8871753B2 (enExample)
EP (1) EP2274288A2 (enExample)
JP (1) JP2011518836A (enExample)
CA (1) CA2722326A1 (enExample)
WO (1) WO2009132202A2 (enExample)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8450335B2 (en) 2008-06-27 2013-05-28 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
AU2013202496B2 (en) * 2008-06-27 2016-08-04 Celgene Car Llc Heteroaryl compounds and uses thereof
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
MX2011002470A (es) * 2008-09-08 2011-04-05 Merck Patent Gmbh Pirimidinas macrociclicas como inhibidores de aurora cinasa.
WO2010085597A1 (en) * 2009-01-23 2010-07-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
JP5918693B2 (ja) 2009-05-05 2016-05-18 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Ｅｇｆｒ阻害剤及び疾患の治療方法
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
US8586584B2 (en) * 2009-10-14 2013-11-19 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8445490B2 (en) 2009-10-14 2013-05-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
HU0900798D0 (en) * 2009-12-21 2010-03-01 Vichem Chemie Kutato Kft 4-phenylamino-pyrimidine derivatives having protein kinase inhibitor activity
WO2011139513A1 (en) 2010-05-04 2011-11-10 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
TWI513694B (zh) * 2010-05-11 2015-12-21 Amgen Inc 抑制間變性淋巴瘤激酶的嘧啶化合物
WO2012019132A2 (en) 2010-08-06 2012-02-09 Cell Signaling Technology, Inc. Anaplastic lymphoma kinase in kidney cancer
JP6068340B2 (ja) 2010-08-10 2017-01-25 セルジーン アヴィロミクス リサーチ， インコーポレイテッド Ｂｔｋ阻害剤のベシル酸塩
US8765944B2 (en) 2010-08-19 2014-07-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
ES2635713T3 (es) 2010-11-01 2017-10-04 Celgene Car Llc Compuestos de heteroarilo y usos de los mismos
NZ710636A (en) 2010-11-01 2017-02-24 Celgene Avilomics Res Inc Heterocyclic compounds and uses thereof
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
HRP20191548T1 (hr) * 2010-11-02 2020-02-21 The Trustees Of Columbia University In The City Of New York Postupci liječenja poremećaja gubitka kose
JP5957003B2 (ja) 2010-11-10 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド 変異体選択的ｅｇｆｒ阻害剤およびその使用
US9133224B2 (en) 2010-11-29 2015-09-15 OSI Pharmaceuticals, LLC Macrocyclic kinase inhibitors
WO2012125603A1 (en) * 2011-03-16 2012-09-20 Cephalon, Inc. Macrocyclic compounds as alk, fak and jak2 inhibitors
US8933066B2 (en) 2011-04-14 2015-01-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP2697230B1 (en) * 2011-04-14 2016-03-30 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
BR112014003798A2 (pt) 2011-08-19 2017-03-01 Merck Sharp & Dohme método para fabricar um composto, e, composto
US8629150B2 (en) 2011-09-28 2014-01-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8697706B2 (en) 2011-10-14 2014-04-15 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US9364476B2 (en) 2011-10-28 2016-06-14 Celgene Avilomics Research, Inc. Methods of treating a Bruton's Tyrosine Kinase disease or disorder
CA3131037A1 (en) 2011-11-30 2013-06-06 Emory University Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
US8916702B2 (en) 2012-02-06 2014-12-23 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
GEP201606560B (en) 2012-03-06 2016-10-25 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases
ES2698298T3 (es) 2012-03-15 2019-02-04 Celgene Car Llc Sales de un inhibidor de quinasa receptor de factor de crecimiento epidérmico
ES2880109T3 (es) 2012-03-15 2021-11-23 Celgene Car Llc Formas sólidas de un inhibidor de la cinasa del receptor del factor de crecimiento epidérmico
EP3459565A1 (en) * 2012-03-29 2019-03-27 The Trustees of Columbia University in the City of New York Methods for treating hair loss disorders
WO2014062636A1 (en) 2012-10-18 2014-04-24 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
WO2014072419A1 (en) 2012-11-08 2014-05-15 Universiteit Antwerpen Novel anti-hiv compounds
US8987264B2 (en) 2012-11-09 2015-03-24 Bristol-Myers Squibb Company 1,3,5-triazine derivatives of spiro bicyclic oxalamide-compounds for treatment of hepatitis C
US8987265B2 (en) 2012-11-09 2015-03-24 Bristol-Myers Squibb Company Substituted 1,3,5-triazine derivatives of fused bicyclic oxalamide compounds for treatment of Hepatitis C
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CN104936952A (zh) 2013-01-25 2015-09-23 百时美施贵宝公司 用于治疗丙型肝炎的胍衍生物
US9624180B2 (en) 2013-01-25 2017-04-18 Bristol-Myers Squibb Company Squaric derivatives for the treatment of hepatitis C
WO2014116766A1 (en) 2013-01-25 2014-07-31 Bristol-Myers Squibb Company Ammonium derivatives for the treatment of hepatitis c
CN104995197A (zh) * 2013-02-07 2015-10-21 百时美施贵宝公司 作为hcv入胞抑制剂的大环化合物
US9868743B2 (en) 2013-02-07 2018-01-16 Bristol-Myers Squibb Company Macrocyclic molecules as HCV entry inhibitors
PE20151274A1 (es) 2013-02-08 2015-09-12 Celgene Avilomics Res Inc Inhibidores de erk y sus usos
WO2014128235A1 (en) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Methods of treating cancer and preventing drug resistance
JP2016510746A (ja) 2013-03-07 2016-04-11 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎の治療のための化合物
WO2014138199A1 (en) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Pyrimidine compounds for the treatment of hepatitis c
MY191366A (en) 2013-03-13 2022-06-20 Forma Therapeutics Inc Novel compounds and compositions for inhibition of fasn
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CN105829293B (zh) * 2013-12-20 2018-11-09 中国人民解放军军事医学科学院毒物药物研究所 新型哌啶氨甲酰类化合物、制备方法及其用途
WO2016025561A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Forms and compositions of an erk inhibitor
WO2016073847A2 (en) * 2014-11-07 2016-05-12 The Regents Of The University Of Michigan Inhibitors of myocardin-related transcription factor and serum response factor (mrtf/srf)-mediated gene transcription and methods for use of the same
JP6847099B2 (ja) 2015-09-29 2021-03-24 バイエル ファーマ アクチエンゲゼルシャフト 新規な大環状スルホンジイミン化合物
ES2819869T3 (es) 2015-10-08 2021-04-19 Bayer Pharma AG Nuevos compuestos macrocíclicos modificados
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
GB2560713A (en) * 2017-03-20 2018-09-26 Eternygen Gmbh Inhibitor of citrate transporter
ES2900199T3 (es) 2017-03-28 2022-03-16 Bayer Ag Novedosos compuestos macrocíclicos inhibidores de PTEFB
US11242356B2 (en) 2017-03-28 2022-02-08 Bayer Aktiengesellschaft PTEFb inhibiting macrocyclic compounds
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
CA3126021A1 (en) * 2019-01-11 2020-07-16 Naegis Pharmaceuticals Inc. Leukotriene synthesis inhibitors
JP2022526713A (ja) 2019-03-21 2022-05-26 オンクセオ がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子
JP2022549506A (ja) 2019-09-27 2022-11-25 ディスク・メディシン・インコーポレイテッド 骨髄線維症および関連状態を処置するための方法
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
KR20220153582A (ko) * 2020-02-14 2022-11-18 솔크 인스티튜트 포 바이올로지칼 스터디즈 마크로시클릭 ulk1/2 억제제
MX2022010128A (es) * 2020-02-18 2023-01-04 Theseus Pharmaceuticals Inc Compuestos macrocíclicos y usos de estos.
EP4149548A4 (en) 2020-05-13 2024-05-08 Disc Medicine, Inc. ANTI-HEMOJUVELIN ANTIBODIES (HJV) FOR THE TREATMENT OF MYELOFIBROSIS
CN113698408B (zh) * 2020-05-22 2025-07-25 武汉朗来科技发展有限公司 Jnk抑制剂、其药物组合物和用途
CN113735856A (zh) * 2020-05-29 2021-12-03 百极弘烨(南通)医药科技有限公司 大环jak抑制剂及其应用
CN113549113A (zh) * 2020-06-17 2021-10-26 广州百霆医药科技有限公司 一种含膦大环化合物及其制备方法与应用
CN114805371B (zh) * 2021-01-19 2024-05-24 江苏开元药业有限公司 含2-氨基嘧啶大环类化合物及其制备方法和用途
WO2023046030A1 (zh) * 2021-09-23 2023-03-30 河南晟翔医药科技有限公司 一种egfr小分子抑制剂、含其的药物组合物及其用途
CA3250447A1 (en) * 2021-12-15 2025-07-09 Whan In Pharmaceutical Co., Ltd. MACROCYCLIC PYRIMIDINE DERIVATIVE, ITS PREPARATION PROCESS, AND PHARMACEUTICAL COMPOSITION INTENDED FOR THE PREVENTION OR TREATMENT OF A NEURODEGENERATIVE DISEASE AND CONTAINING THIS DERIVATIVE AS AN ACTIVE INGREDIENT
CN114394974B (zh) * 2022-03-25 2022-12-06 中国药科大学 多取代三芳基大环化合物与应用
AU2023323738A1 (en) * 2022-08-08 2025-01-09 Ajax Therapeutics, Inc. Heterocyclic amide and urea compounds as jak2 inhibitors
WO2024094171A1 (zh) * 2022-11-04 2024-05-10 江苏恒瑞医药股份有限公司 取代的氨基嘧啶类化合物、其制备方法及其在医药上的应用
CN116496234B (zh) * 2023-02-09 2024-09-13 江苏润安制药有限公司 一种盐酸乌拉地尔关键中间体的制备方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CN1332743A (zh) 1998-06-04 2002-01-23 艾博特公司 抑制细胞粘附抗炎化合物
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
JP4516690B2 (ja) 1998-08-11 2010-08-04 ノバルティス アーゲー 血管形成阻害活性を有するイソキノリン誘導体
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GEP20053479B (en) 1999-12-10 2005-03-25 Pfizer Prod Inc Pyrrolo[2,3-d]Pyrimidine Compounds, Pharmaceutical Composition Containing the Same and Use
CN100379734C (zh) * 1999-12-24 2008-04-09 阿文蒂斯药物有限公司 氮杂吲哚类化合物
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0011527D0 (en) 2000-05-12 2000-06-28 Unilever Plc Bleach catalyst and composition and method for bleaching a substrate
DE60105023T2 (de) 2000-06-28 2005-08-18 Smithkline Beecham P.L.C., Brentford Nassvermahlungsverfahren
AU2002337142B2 (en) 2001-09-19 2007-10-11 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
DK1441737T3 (da) 2001-10-30 2006-11-13 Novartis Ag Staurosporin-derivater som inhibitorer af FLT3-receptor-tyrosinkinase-aktivitet
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AU2003259063A1 (en) * 2002-07-25 2004-02-16 University Of Florida Method for incorporation of pentafluorosulfanyl (sf5) substituents into aliphatic and aromatic compounds
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
CA2515132C (en) 2003-02-07 2012-01-03 Vertex Pharmaceuticals Incorporated Heteroaryl substituted pyrroles useful as inhibitors of protein kinases
US7151096B2 (en) * 2003-03-05 2006-12-19 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
ES2263862T3 (es) 2003-03-07 2006-12-16 Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Ensayo de quinasa de linfoma anaplasico, sus reactivos y composiciones.
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
SE0301372D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
SE0301373D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
GB0316109D0 (en) 2003-07-09 2003-08-13 Dystar Textilfarben Gmbh & Co Water-soluble macrocyclic azacalixarenes
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
WO2005009967A2 (en) 2003-07-22 2005-02-03 Janssen Pharmaceutica, N.V. Quinolinone derivatives as inhibitors of c-fms kinase
DE10333183A1 (de) 2003-07-22 2005-02-17 Daimlerchrysler Ag Verfahren zum Betrieb eines Antriebsstranges für ein Kraftfahrzeug
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
JP2005220116A (ja) 2004-02-09 2005-08-18 Japan Science & Technology Agency １，３，５−トリアジン環を環構成要素として含むシクロファン型化合物、その製造方法、中間体及びその利用
HRP20161751T1 (hr) 2004-05-13 2017-04-07 Icos Corporation Kinazolinoni kao inhibitori humane fosfatidilinozitol 3-kinaze delta
AU2005309019A1 (en) 2004-11-24 2006-06-01 Novartis Ag Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors
MY169441A (en) 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
EP1674470A1 (en) 2004-12-22 2006-06-28 Schering Aktiengesellschaft Sulfonamido-macrocycles as Tie2 inhibitors
US20060194823A1 (en) * 2004-12-22 2006-08-31 Georg Kettschau Sulfonamido-macrocycles as Tie2 inhibitors and the salts thereof, a pharmaceutical composition comprising these compounds, the method of preparing and the use thereof
EP1710246A1 (en) * 2005-04-08 2006-10-11 Schering Aktiengesellschaft Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer
EA017545B1 (ru) 2005-06-30 2013-01-30 Янссен Фармацевтика Н.В. Циклические анилино-пиридинотриазины в качестве ингибиторов gsk-3
PH12012501003B1 (en) 2005-11-16 2018-04-06 Cti Biopharma Corp Oxygen linked pyrimidine derivatives
ATE525374T1 (de) * 2005-12-13 2011-10-15 Incyte Corp Heteroarylsubstituierte pyrroloä2,3-büpyridine und pyrroloä2,3-büpyrimidine als januskinaseinhibitoren
EP1803723A1 (de) 2006-01-03 2007-07-04 Bayer Schering Pharma Aktiengesellschaft (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximid derivate als selektive inhibitoren der aurora kinase zur behandlung von krebs
EP1870416A1 (en) * 2006-06-21 2007-12-26 Bayer Schering Pharma Aktiengesellschaft Sulphonamido-macrocycles as tie2 inhibitors
EP1873159A1 (en) 2006-06-21 2008-01-02 Bayer Schering Pharma Aktiengesellschaft Substituted sulphonamido-macrocycles as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same

Similar Documents

Publication Publication Date Title
JP2011518836A5 (enExample)
JP5759470B2 (ja) オレキシン受容体調節因子としての二置換オクタヒドロピロロ［３，４−ｃ］ピロール
US9855269B2 (en) Aminoquinazoline and pyridopyrimidine derivatives
US8871753B2 (en) Macrocyclic compounds and their use as kinase inhibitors
JP6170121B2 (ja) オレキシン受容体調節因子としての縮合複素環式化合物
DE602004011401T2 (de) Benzazepinderivate als histamin-h3-antagonisten
JP5847087B2 (ja) オレキシン受容体調節因子としての縮合複素環式化合物
CN112638373A (zh) 细胞周期蛋白依赖性激酶抑制剂
JP2013503846A (ja) ベンズイミダゾール誘導体
JP2010513444A5 (enExample)
JP2016523911A5 (enExample)
CA2664810A1 (en) Substituted sulfonamide derivatives
JP2017516826A (ja) 炎症性および自己免疫性の病気の処置のためのｍｔｈ１阻害剤
JP2015522057A (ja) ＲＯＲｃモジュレーターとしてのアリールスルタム誘導体
AU2006236387A1 (en) Subtituted heteroaryl CB1 antagonists
EP2440204A1 (en) Nicotinamide compounds useful as kinase modulators
JP2019519484A5 (enExample)
JP2011503194A5 (enExample)
JP2013533300A (ja) ブルトン型チロシンキナーゼの阻害剤
JP2018520201A5 (enExample)
AU2014248763A1 (en) Substituted piperidine compounds and their use as orexin receptor modulators
AU2004273771A1 (en) 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (GSK-3)
US20090227555A2 (en) Novel Pyridine Compounds
JP6304492B2 (ja) トリアジノン化合物及びｔ型カルシウムチャネル阻害剤